AI Article Synopsis
- A library of 14 minimally cytotoxic diterpenoid-like compounds was tested for antimicrobial activity against various bacteria, with some showing promise against mycobacteria.
- One compound, featuring a phenethyl alcohol core, demonstrated the strongest anti-mycobacterial effects, with a minimum inhibitory concentration (MIC) of 23.4 mg/L.
- Additionally, this compound was found to alter bacterial metabolism significantly, suggesting potential for further optimization in medicinal chemistry to develop more effective treatments.
Article Abstract
A library of 14 minimally cytotoxic diterpenoid-like compounds (CC > 70 μM on HepG2 human liver cells) was screened against , , and to determine antimicrobial activity. Some compounds with a phenethyl alcohol (PE) core substituted with a β-cyclocitral derivative demonstrated anti-mycobacterial activity, with the most active being compound (MIC = 23.4 mg/L, IC = 0.6 mg/L). Lower activity was exhibited against , while no activity was displayed against Low cytotoxicity was re-confirmed on HepG2 cells and additionally on RAW 264.7 murine macrophages (SI for both cell lines > 38). The sub-lethal (IC at 6 h) effect of compound on was examined through untargeted metabolomics and compared to untreated bacteria and bacteria treated with sub-lethal (IC at 6 h) concentrations of the antituberculosis drugs ethambutol, isoniazid, kanamycin, and streptomycin. The study revealed that compound acts differently from the reference antibiotics and that it significantly affects amino acid, nitrogen, nucleotides and folate-dependent one-carbon metabolism of , giving some insights about the mode of action of this molecule. A future medicinal chemistry optimization of this new anti-mycobacterial core could lead to more potent molecules.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603307 | PMC |
| http://dx.doi.org/10.3389/fmicb.2019.01444 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Frontiers in Fighting Mycobacterial Infections: Venom-Derived Peptides.
Probiotics Antimicrob Proteins
January 2025
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Notwithstanding the indefatigable endeavors to develop effective anti-mycobacterial therapies, mycobacterial infections still present a tough problem for medicine today. The problem is further complicated by the disquieting surge of drug-resistant mycobacterial pathogens, which considerably narrows the existing therapeutic options. Thus, there is a genuine need to discover novel anti-mycobacterial drugs.
View Article and Find Full Text PDFAnti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers.
ACS Infect Dis
January 2025
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Developing new classes of drugs that are active against infections caused by is a priority for treating and managing this deadly disease. Here, we describe screening a small library of 20 DNA gyrase inhibitors and identifying new lead compounds. Three structurally diverse analogues were identified with minimal inhibitory concentrations of 0.
View Article and Find Full Text PDFA conserved human CD4+ T cell subset recognizing the mycobacterial adjuvant, trehalose monomycolate.
J Clin Invest
December 2024
Department of Molecular Immunology, Research Institute for Microbial Diseas, Osaka University, Suita, Japan.
Mycobacterium tuberculosis causes human tuberculosis. As mycobacteria are protected by thick lipid cell wall, humans have developed immune responses against diverse mycobacterial lipids. Most of these immunostimulatory lipids are known as adjuvants acting through innate immune receptors, such as C-type lectin receptors.
View Article and Find Full Text PDFAntimycobacterial Activity of Solid Lipid Microparticles Loaded with Ursolic Acid and Oleanolic Acid: In Vitro, In Vivo, and Toxicity Assessments.
Microorganisms
October 2024
Nanobios Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Article Synopsis
- Ursolic acid (UA) and oleanolic acid (OA) are natural compounds with anti-mycobacterial properties but have poor solubility, limiting their use in treatment.
- Researchers developed solid lipid microparticles (SLMs) to effectively deliver UA and OA, demonstrating their ability to inhibit both drug-sensitive and multidrug-resistant tuberculosis (Mtb) in lab tests.
- In mouse models, the delivery of SLMs via inhalation significantly reduced bacterial loads and improved survival rates without causing toxicity, showcasing their potential as a safe and effective treatment option for tuberculosis.
Antioxidant: Antimycobacterial and Antibiofilm Activities of Acetone Extract and Subfraction Jacq. ex Willd. Against .
Antibiotics (Basel)
October 2024
Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Private Bag X1106, Sovena 0727, South Africa.
Tuberculosis is a worldwide prevalent and recurring disease that contributes significantly to high mortality rates. This study aimed to investigate the antioxidant, anti-mycobacterial, and antibiofilm activities of acetone crude extract. The crude acetone extract was fractionated using column chromatography and characterized by liquid chromatography-mass spectroscopy (LC-MS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!